Over the past year, biopharmaceutical companies have worked at an unprecedented speed to research and develop COVID-19 vaccines, treatments and diagnostics – supported by the innovation ecosystem along the way. As regulatory authorities continue to monitor the safety and efficacy of these innovations and authorize them for public use, it is important for patients to also feel confident in and accept inoculation once vaccine supply is available.
A recent report from the Geneva Network is highlighting the important role intellectual property (IP) has played throughout the COVID-19 pandemic, encouraging public-private partnerships, enabling global knowledge-sharing and promoting innovative collaboration.
The COVID-19 pandemic may have disrupted most aspects of life this year, but it has also spurred unprecedented innovation. Backed by strong intellectual property protections, innovative biopharmaceutical companies were able to respond to the pandemic swiftly and utilize decades of research and development efforts on viruses similar to COVID-19 to develop vaccines and therapies in record time.
Regional leaders recently convened for two critical meetings – the 27th annual APEC Economic Leaders’ Meeting and the ASEAN Health Summit – to discuss various economic challenges imposed by the COVID-19 pandemic and its impact on the health of patients throughout Southeast Asia.
Explore the Countries
Indonesia has achieved significant health milestones, but rising rates of NCDs bring new challenges.
Malaysia can attract new foreign investment and improve health outcomes by better protecting innovation and reducing bureaucratic delays.
Increasing public-private partnerships in the Philippines will bring health care innovation to a rapidly growing population
Health care is poised to become a major economic driver in Thailand in the coming years.
The success of Singapore’s health care system can be attributed to strong policies and an integrated health system.